Molecular Diagnostics, Circuit-Calming Modulators, and Controlled Neuroplastogens: Emerging Strategies in Precision Neuropsychiatric Therapeutics
Anna C. Renner, Robert B. Kargbo
ACS Medicinal Chemistry Letters December 16, 2025 DOI: 10.1021/acsmedchemlett.5c00716 via OpenAlex
Summary
AI-generated from the abstractThree new approaches in neuropsychiatric therapeutics are converging: a blood test measuring FOXG1 gene expression for objective PTSD detection; benzocyclobutenyl-methylamine compounds that reduce excessive neuronal firing; and a sublingual 5-MeO-DMT formulation that promotes neuroplasticity without hallucinations. These advances link molecular diagnostics, targeted neural circuit modulation, and scalable treatments for affective disorders.
Study at a glance
| Characteristics | Review Peer reviewed |
|---|---|
| Keywords | Neuroscience Computer science Scalability Computational biology Precision medicine |
| Key finding | Three complementary inventions—a FOXG1-based blood diagnostic for PTSD, benzocyclobutenyl-methylamine modulators for neuronal hyperexcitability, and sublingual 5-MeO-DMT for nonhallucinogenic neuroplasticity—form a convergent framework for neuropsychiatric therapeutics. |
Abstract
New inventions introduce complementary advances across neuropsychiatric therapeutics: a blood-based gene-expression diagnostic centered on FOXG1 for objective PTSD detection; benzocyclobutenyl-methylamine modulators that normalize neuronal hyperexcitability; and templated-carrier sublingual 5-MeO-DMT formulations enabling controlled, nonhallucinogenic neuroplasticity. Together, these approaches form a convergent framework linking molecular diagnostics, targeted circuit modulation, and scalable affective therapeutics.